Dr Qin Huanlong is a Shanghai-based clinician-researcher at Shanghai Tenth People’s Hospital, Tongji University School of Medicine, specializing in gut microbiota and fecal microbiota transplantation (FMT). He is part of the Chinese clinical research ecosystem that has conducted some of the world’s largest and most systematic national studies on FMT in children with autism spectrum disorder, an area where China has taken a uniquely large-scale, coordinated approach. Dr. Qin has contributed to multicenter clinical programs and long-term observational cohorts involving hundreds of pediatric autism patients, evaluating both gastrointestinal and behavioral outcomes following microbiota-based interventions. His work reflects China’s capacity to move beyond small pilot trials toward population-level clinical evidence in microbiome-targeted therapies. In addition to autism research, he is actively involved in FMT applications across digestive and functional intestinal diseases, helping to refine clinical protocols and safety monitoring. His research sits at the forefront of the gut–brain axis, bridging gastroenterology, microbiome science, and neurodevelopmental research. Through hospital-embedded clinical research centers, Dr. Qin contributes to shaping how microbiota therapies are evaluated, standardized, and scaled in real-world medical practice.
Dr. Huanlong Qin
Professor, MD
People's Republic of China